newsfilter
← Latest News
GlobeNewswire·

Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target

BIOA
  • Deep Origin & BioAge Labs announced a multi-target AI-driven drug discovery collaboration on Oct. 14, 2026.
  • The partnership reached its first milestone with novel small-molecule hits identified computationally by Deep Origin & validated in BioAge's wet lab against a new target.
  • Deep Origin utilizes hybrid AI & physics-based models to screen candidates against BioAge's targets, ensuring hits meet medicinal chemistry criteria before lab validation.
  • BioAge retains responsibility for verifying hit activity, leading hit-to-lead optimization, selecting development candidates, & managing clinical development.
  • Deep Origin's virtual screening architecture uses proprietary engines DODock & DOScore to predict small molecule binding orientation & affinity.
  • The company reported a 30.6% hit rate on CD73 in an August 2026 bioRxiv preprint, approximately 100 times the rate of prior machine-learning screens for the same target.
  • Deep Origin delivered multiple structurally distinct hits against BioAge's first target in under three months, enabling BioAge to advance the target into hit-to-lead optimization.
  • The agreement grants BioAge access to Deep Origin's later-stage computational tools, including free energy perturbation calculations & virtual human avatars for toxicology prediction.
  • BioAge is developing BGE-102, an NLRP3 inhibitor for inflammatory diseases, with Phase 2 cardiovascular data expected in late 2026 & diabetic macular edema data expected in late 2027.
  • Deep Origin is backed by over $50 million in capital & more than $32 million in non-dilutive funding, including an ARPA-H CATALYST award.